Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial [0.03%]
一周一次司美格鲁肽2.0毫克与1.0毫克治疗2型糖尿病疗效和安全性的随机双盲IIIb期临床试验（SUSTAIN FORTE研究）
Juan P Frías,Pernille Auerbach,Harpreet S Bajaj et al.
Juan P Frías et al.
Background: Semaglutide is an effective treatment for type 2 diabetes; however, 20-30% of patients given semaglutide 1·0 mg do not reach glycaemic treatment goals. We aimed to investigate the efficacy and safety of once-...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Sep;9(9):563-574. DOI:10.1016/S2213-8587(21)00174-1 2021
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
René Rizzoli,Emmanuel Biver,Tara C Brennan-Speranza
René Rizzoli
Osteoporotic or fragility fractures affect one in two women and one in five men who are older than 50. These events are associated with substantial morbidity, increased mortality, and an impaired quality of life. Recommended general measure...
Karl J Neff,Carel W le Roux
Karl J Neff
Principles for virtual health care to deliver real equity in diabetes [0.03%]
虚拟保健的基本原则以实现糖尿病治疗的真正公平性
David Kerr,Ashutosh Sabharwal
David Kerr
Long-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study [0.03%]
瑞典肥胖手术受试者的长期贫血风险研究结果
Kari Johansson,Per-Arne Svensson,Jonas Söderling et al.
Kari Johansson et al.
Background: Nutritional deficiencies, such as iron and vitamin B12 deficiencies, are potential adverse consequences of bariatric surgery. Long-term data on anaemia after bariatric surgery are largely lacking. We aimed to ...
The contribution of structural racism to metabolic health disparities in the USA [0.03%]
结构性种族主义对美国代谢健康差异的贡献
Sherita Hill Golden
Sherita Hill Golden
Jay S Skyler
Jay S Skyler
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [0.03%]
伊马替尼治疗新发1型糖尿病患者的疗效：一项多中心随机双盲安慰剂对照二期临床试验
Stephen E Gitelman,Brian N Bundy,Ele Ferrannini et al.
Stephen E Gitelman et al.
Background: Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it...
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes [0.03%]
2型糖尿病的治疗：挑战、希望和预期成功
Michael A Nauck,Jakob Wefers,Juris J Meier
Michael A Nauck
Despite the successful development of new therapies for the treatment of type 2 diabetes, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 inhibitors, the search for novel treatment options that c...